Company

TearSolutions, Inc.

TearSolutions, Inc. develops Lacripep, a peptide therapy for dry eye disease and other ocular surface diseases.

About

Founded in 2013 in Charlottesville, US, by Gordon Laurie and Mark Logan, TearSolutions, Inc. develops Lacripep, a peptide therapy derived from the Lacritin protein for Dry Eye Disease and other ocular surface diseases. Anil Asrani is CEO. The company raised USD 12.71 mn in a Series B round in September 2024, bringing its total raised to USD 12.71 mn, and it has completed 4 deals to date.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in